Results for this period
Third quarter1 July 2025 to 31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales and gross profit increased due to expanded sales associated with an increase in cases, particularly in the cardiovascular and orthopedics fields, and the acquisition of new customers. However, selling, general and administrative expenses increased due to personnel costs resulting from hiring and base-pay increases, as well as higher logistics costs resulting from increases in delivery rates and shipment volumes. As a result, operating profit, ordinary profit and profit attributable to owners of the parent decreased.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Net Sales | ¥227,680 million (YoY +3.7%) |
| Operating profit | ¥1,923 million (YoY -5.1%) |
| Ordinary income | ¥2,294 million (YoY -4.8%) |
| Profit attributable to owners of the parent | ¥1,282 million (YoY -6.5%) |
| Net income per share | ¥57.66 |
| Equity ratio | End of the current fiscal period 16.7% / End of previous period 18.1% |
| Total assets | ¥125,160 million |
| Net assets | ¥20,902 million |
| Full-year earnings forecast | Net Sales ¥305,000 million (YoY +5.6%) / Operating profit ¥1,750 million (YoY -6.7%) / Ordinary income ¥2,300 million (YoY -5.1%) / Net income ¥1,300 million (YoY -5.5%) |
| Annual Dividend Forecast | ¥20.00 → ¥20.00（0.0%） |
| Segment revenue | Medical Device Sales Business ¥222,909,507 thousand (YoY +3.7%), Nursing-care and welfare business ¥4,770,923 thousand (YoY +4.1%) |
| Segment profit | Medical Device Sales Business ¥7,506,452 thousand (YoY -9.1%), Nursing-care and welfare business ¥466,817 thousand (YoY +14.1%) |
| Depreciation and amortization | ¥1,401,408 thousand |
| Impairment loss | ¥3,801 thousand, comprising fixed assets (¥3,645 thousand for the Medical Equipment Sales Business and ¥156 thousand for the Nursing Care and Welfare Business) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥6,048 thousand, Gain on sale of investment securities ¥115,769 thousand / Extraordinary loss Loss on sale of fixed assets ¥126 thousand, Loss on Disposal of Fixed Assets ¥16,391 thousand, Impairment Losses ¥3,801 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社レップス / Excluded Number of companies 1 / Company name ノアインターナショナル株式会社 |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 22,238,217 Shares |
| Treasury Shares at Period-End | 958 Shares |
| Factors Behind Changes in Business Performance | Net sales and gross profit increased due to expanded sales associated with an increase in cases, particularly in the cardiovascular and orthopedics fields, and the acquisition of new customers. However, selling, general and administrative expenses increased due to personnel costs resulting from hiring and base-pay increases, as well as higher logistics costs resulting from increases in delivery rates and shipment volumes. As a result, operating profit, ordinary profit and profit attributable to owners of the parent decreased. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales expanded due to an increase in cases, particularly in the cardiovascular and orthopedics fields, and the acquisition of new customers. However, selling, general and administrative expenses increased because of higher personnel costs resulting from hiring and base-pay increases accompanying the expansion of the business, as well as higher logistics costs resulting from increases in delivery rates and shipment volumes.